TNFSF11
ENSG00000120659
Target class
Secreted protein
Chromosome
13
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- TNFSF11
- Gene name
- TNF superfamily member 11
- Gene symbol
- TNFSF11
- Protein name
- Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form]
- TRANCE
- RANKL
- OPGL
- ODF
- CD254
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 14.71
- Tissue specificity (Gini)
- 0.931
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:8600
- Protein interaction confidence
- 0.820407
- Protein interaction partners
- 54
- R-HSA-5668541
- R-HSA-5669034
- R-HSA-5676594
- R-HSA-9856649
- End position
- 42608013
- Start position
- 42562736
- Chromosome
- 13
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type II membrane protein.
- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane
- Single-pass type II membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm .
- SUBCELLULAR LOCATION: [Tumor necrosis factor ligand superfamily member 11, soluble form]: Secreted .
- Tissue specificity (tau)
- 0.994331
- Expression inequality (Gini)
- 0.930776
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 14.71
- Testis
- 1.66
- Small Intestine - Terminal Ileum
- 0.62
- Liver
- 0.34
- Spleen
- 0.23
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes14.71
- Testis1.66
- Small Intestine - Terminal Ileum0.62
- Liver0.34
- Spleen0.23
- Minor Salivary Gland0.16
- Colon - Transverse0.16
- Esophagus - Mucosa0.11
- Skin - Not Sun Exposed (Suprapubic)0.11
- Vagina0.09
- Adipose - Visceral (Omentum)0.08
- Brain - Hypothalamus0.08
- Lung0.06
- Kidney - Cortex0.06
- Pituitary0.06
- Skin - Sun Exposed (Lower leg)0.05
- Bladder0.05
- Artery - Coronary0.05
- Pancreas0.04
- Esophagus - Muscularis0.04
- Artery - Tibial0.04
- Thyroid0.04
- Colon - Sigmoid0.04
- Prostate0.04
- Breast - Mammary Tissue0.03
And 29 more, listed on the interactive page.
- GO:0002548
- GO:0019221
- GO:0030316
- GO:0033209
- GO:0034112
- GO:0043410
- GO:0045672
- GO:0045780
- GO:0045944
- GO:0050870
- GO:0070374
- GO:1901224
- GO:1902533
- GO:0005576
- GO:0005886
- GO:0005125
- GO:0005515
Related records
Trials (284)
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
- A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
- A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
- A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
- A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
- A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection
- A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
- A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
- A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
- A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
- A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
- A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
- A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
- A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
- A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
- A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
- A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
- A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Drugs (1)
- Denosumab Tumor necrosis factor ligand superfamily member 11 inhibitor